PT/INR <. x ULN and PTT (aPTT) <. x ULN
PTT ? . times institutional ULN
PTT =< . x ULN
PTT > . x ULN
Abnormal coagulation profile (PT or INR, PTT) > .x ULN
PT and PTT <. x ULN
PT and PTT w/in ?. ULN
PHASE IB: PT (or INR) and PTT =< . x ULN
PTT & INR within institutional limits.
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: PT and PTT less than or equal to . times the institutional upper limit of normal
Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigators discretion
Normal PT/INR and PTT;
FULL STUDY INCLUSION CRITERIA: Partial thromboplastin time (PTT) or activated PTT (aPTT) =< . x ULN (CTCAE grade =< )\r\n* Note: patients on stable dose of anti-coagulation therapy will be allowed to participate if they have no sign of bleeding or clotting and INR / PT and PTT / aPTT test results are compatible with the acceptable benefit-risk ratio at the investigators discretion
Acceptable coagulation status: INR ?. x ULN and PTT ?. x ULN.
PT and PTT <. ULN
Patients must have INR and PTT values ? .X ULN for the reference laboratory.
PTT WNL; if patient on warfarin for prophylactic clot presentation for indwelling catheter, PT/PTT may be +/-  %
Abnormal level of platelets (< ), PT (>) or PTT (>), and INR > ..
PT and PTT ? . X ULN
Patients with PT/PTT above the upper limit of normal
PTT =< . x ULN unless on anticoagulation therapy, in which case PT or PTT should be in the therapeutic range
For patients on Coumadin, INR/prothrombin time (PT)/PTT must be > . ULN
PTT ?. ULN
INR < . or PTT value < . x upper limit of normal (ULN) at study entry
Bleeding disorder (INR > ULN and PTT > ULN)
PTT <. ULN
MF PATIENTS: PT and PTT =< . x ULN
INR and PTT within . X institutional ULN
PT/INR <. x ULN and PTT (aPTT) <. x ULN
PT/INR, PTT, and fibrinogen within institutional acceptable limits
For patients not taking warfarin: INR ?. or PT ?.  ULN; and either PTT or aPTT ?.  ULN. Patients taking warfarin should be on a stable dose that results in a stable INR <..
The patient has a PT (or INR) and PTT up to .ULN
PT/INR <. x ULN and PTT (aPTT) <. x ULN (When treated with warfarin or other vitamin K antagonists, then INR ?.).
PT/INR <. x ULN and PTT/ aPTT <. x ULN
PT/PTT > the institution ULN